Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640748 | 0.88 | OPRM1 (0.36) | TNKSTNKS2OPRM1OPRL1 | |
| SCHEMBL12899137 | 0.81 | CCR5 (0.32) | CCR5AVPR1ALMNATNKSTNKS2 | |
| SCHEMBL12084275 | 0.79 | OPRM1 (0.52) | OPRM1OPRL1 | |
| SCHEMBL12084853 | 0.79 | AVPR1A (0.33) | CCR5AVPR1ATNKSTNKS2MEN1 | |
| SCHEMBL13640944 | 0.79 | MAP3K14 (0.34) | LMNAOPRM1OPRL1 | |
| SCHEMBL12084489 | 0.75 | KDM4E (0.46) | AVPR1AMEN1KMT2A | |
| SCHEMBL13643962 | 0.74 | CCR5 (0.33) | CCR5AVPR1ALMNATNKSTNKS2 | |
| SCHEMBL12292610 | 0.73 | OPRM1 (0.36) | CCR5AVPR1ATNKSTNKS2OPRM1 | |
| SCHEMBL13212943 | 0.72 | AVPR1A (0.43) | CCR5AVPR1ALMNATNKSTNKS2 | |
| SCHEMBL13000366 | 0.71 | OPRM1 (0.42) | OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | CCR5 293/4885AVPR1A 238/4885LMNA 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.